phosphorus has been researched along with cinacalcet in 129 studies
| Studies (phosphorus) | Trials (phosphorus) | Recent Studies (post-2010) (phosphorus) | Studies (cinacalcet) | Trials (cinacalcet) | Recent Studies (post-2010) (cinacalcet) |
|---|---|---|---|---|---|
| 48,074 | 1,126 | 17,139 | 1,070 | 155 | 627 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 61 (47.29) | 29.6817 |
| 2010's | 66 (51.16) | 24.3611 |
| 2020's | 2 (1.55) | 2.80 |
| Authors | Studies |
|---|---|
| Blaisdell, PW; Brenner, RM; Coburn, JW; Goodman, WG; Lindberg, JS; Liu, W; Martin, KJ; Moe, SM; Sprague, SM; Turner, SA | 1 |
| Adler, S; Bushinsky, DA; Liu, W; McCary, LC; Quarles, LD; Rosansky, SJ; Sherrard, DJ; Turner, SA | 1 |
| Balandrin, MF; Colloton, M; Fox, J; Harris, R; Heaton, WH; Karbon, W; Lacey, D; Martin, D; Miller, M; Nemeth, EF; Qi, M; Rishton, G; Scherrer, J; Scully, S; Shatzen, E; Van Wagenen, BC | 1 |
| Abu-Alfa, AK; Avram, MM; Block, GA; Braun, J; Cohen, RM; Coyne, DW; Cunningham, J; de Francisco, AL; Drüeke, TB; Evenepoel, P; Fournier, A; Goodman, WG; Hercz, G; Locatelli, F; Martin, KJ; McCary, LC; Messa, P; Moe, SM; Olson, KA; Suranyi, MG; Turner, SA; Zani, VJ | 1 |
| Curhan, G | 1 |
| Ureña Torres, P | 1 |
| Szczech, LA | 1 |
| Fukagawa, M; Nishi, H | 1 |
| Nagano, N | 1 |
| Block, GA; Chertow, GM; Coburn, JW; Cunningham, J; Drüeke, TB; Goodman, WG; Martin, KJ; McCary, LC; Moe, SM; Olson, KA; Quarles, LD; Sherrard, DJ; Turner, SA | 1 |
| Albizem, MB; Borah, MF; Clark, RV; Coburn, JW; Culleton, B; Guo, MD; Husserl, FE; Klassen, PS; Lindberg, JS; Roger, SD; Shapiro, WB; Wong, G | 1 |
| de Francisco, AL | 2 |
| Cattley, RC; Colloton, M; Henley, C; Lacey, D; Martin, D; Shatzen, E; Towler, DA | 1 |
| Charytan, C; Chonchol, M; Coburn, JW; Herman, J; Klassen, PS; Lien, YH; Liu, W; McCary, LC; Pichette, V | 1 |
| Adler, S; Albizem, MB; Bommer, J; Cunningham, J; Goodman, WG; Guo, MD; Moe, SM; Rosansky, SJ; Sprague, SM; Urena-Torres, P; Zani, VJ | 1 |
| Andrés, E; Ballarín, J; Barceló, P; Bover, J; Ortiz-Herbener, F | 1 |
| Bushinsky, DA; Campbell, P; Charytan, C; Curzi, M; Goodman, WG; Guo, MD; Jüppner, H; Kaplan, MR; Martin, KJ; McCary, LC; Nassar, G; Sherrard, DJ; Turner, SA | 1 |
| Cunningham, J | 1 |
| Dong, BJ | 1 |
| Asplin, JR; Bushinsky, DA; Laplante, K | 1 |
| Drüeke, TB; Landais, P | 1 |
| Imanishi, Y; Inaba, M | 1 |
| Fukagawa, M | 1 |
| Ashfaq, A; Gitman, M; Singhal, PC | 1 |
| Bell, S; Casey, L; Chonchol, M; Parker, M; Spiegel, DM | 1 |
| Bruns, DE; D'Amour, P; Hanks, JB; Henrich, LM; Levine, MA; Rogol, AD | 1 |
| Fadem, SZ; Moe, SM | 1 |
| Adams, JS; Collins, MT; Geller, JL; Kelly, MH; Khosravi, A; Riminucci, M | 1 |
| Cincotta, E; Doshi, MD; El-Amm, JM; Gruber, SA; Losanoff, JE; Migdal, S; Morawski, K; Singh, A; Sternbauer, D; West, MS | 1 |
| Antonelli, M; Basile, C; Giammaria, B; Lomonte, C; Losurdo, N; Marchio, G | 1 |
| Akizawa, T; Fukagawa, M; Iwasaki, M; Koshikawa, S; Tsukamoto, Y; Uchida, E; Yumita, S | 1 |
| Bajo, MA; Codoceo, R; Del Peso, G; Díez, JJ; Gancedo, PG; Gil, F; Iglesias, P; Martinez-Ara, J; Miguel, JL; Sánchez, C; Selgas, R | 1 |
| Hanba, Y; Negi, S; Ooura, M; Shigematsu, T | 1 |
| Bos, WJ; Bouman, K; Braun, J; Brink, H; Carter, D; Frazão, JM; Graf, H; Locatelli, F; Macário, F; Maduell, F; Messa, P; Molemans, B; Reichel, H; Saha, H; Torregrosa, V; von Albertini, B; Wilkie, M; Yaqoob, M; Zani, VJ | 1 |
| Ais, G; Díez, JJ; Fernández Pardo, E; García Arévalo, C; González, A; Iglesias, P; Tajada, P | 1 |
| Block, GA; Bushinsky, DA; Chertow, GM; Chi, EM; Sugihara, J; Turner, SA; Zeig, S | 1 |
| Negri, AL | 1 |
| Akiba, T; Akizawa, T; Iwasaki, M; Koshikawa, S; Tsukamoto, Y; Uchida, E | 1 |
| Drueckler, E; Fischer, DC; Haffner, D; Kundt, G; Muscheites, J; Wigger, M | 1 |
| Fukagawa, M; Komaba, H; Tanaka, M | 1 |
| Ceglia, L; Dawson-Hughes, B; Harris, SS; Rasmussen, HM | 1 |
| Cointault, O; Durand, D; Esposito, L; Gandia, P; Gennero, I; Guitard, J; Kamar, N; Lavayssière, L; Rostaing, L; Spataru, L | 1 |
| Charytan, C; Corry, DB; Fishbane, S; Goodman, WG; Ling, X; Rappaport, K; Roppolo, M; Shapiro, WB; Turner, S; Vicks, SL | 1 |
| Serra, AL; Wuhrmann, C; Wüthrich, RP | 1 |
| Drüeke, TB | 1 |
| Matsuoka, S; Sato, T; Tominaga, Y; Uno, N | 1 |
| Tahara, H | 1 |
| Fukagawa, M; Komaba, H | 1 |
| Drüeke, TB; Ritz, E | 1 |
| Abboud, HE; Albizem, MB; Block, GA; Charytan, C; Chonchol, M; de Francisco, AL; Jolly, S; Kaplan, M; Kubo, Y; Locatelli, F; Mix, TC; Roger, SD; Sarkar, S | 1 |
| Arko, C; Block, GA; Li, Q; Liu, J; Nieman, K; Persky, M; St Peter, WL | 1 |
| Kalantar-Zadeh, K; Kovesdy, CP | 1 |
| Alonso, M; Andrés, E; Ballarín, J; Bover, J; Canal, C; Farré, N; Olaya, MT; Quílez, B | 1 |
| Filson, J; Nguyen, TV | 1 |
| Bos, WJ; Bouman, K; Braun, J; Brink, H; Carter, D; Frazão, JM; Graf, H; Macário, F; Maduell, F; Messa, P; Pontoriero, G; Reichel, H; Saha, H; Torregrosa, V; von Albertini, B; Wilkie, M; Yaqoob, M; Zani, VJ | 1 |
| Ashman, N; Baños, A; Bencova, V; Fouque, D; Jacobson, SH; Leavey, S; Malberti, F; Os, I; Rix, M; Ryba, M; Saha, H; Ureña, P; Vervloet, M; Zani, V; Zitt, E | 1 |
| Brandenburg, V; Cozzolino, M | 1 |
| Himeno, Y; Shigeno, K; Sugimoto, T; Sumi, M; Suzuki, K; Tokumoto, A; Yano, S | 1 |
| Curzi, MP; Evenepoel, P; González, MT; Husserl, FE; Kopyt, N; Mix, C; Sprague, SM; Sterling, LR; Wong, G | 1 |
| Yokoyama, K | 1 |
| Hirukawa, T; Kakuta, T; Kanai, G; Saito, A; Sato, A; Sawaya, A; Tanaka, R | 1 |
| Shaheen, FA; Souqiyyeh, MZ | 1 |
| Finch, JL; Lane, N; Nakamura, H; Shahnazari, M; Slatopolsky, E; Tokumoto, M; Yao, W | 1 |
| Imanishi, Y; Inaba, M; Ishimura, E; Kurajoh, M; Nagayama, H; Nishizawa, Y; Okuno, S; Shoji, S; Yamada, S; Yamakawa, T | 1 |
| Taniguchi, M | 1 |
| Koiwa, F; Maruta, Y | 1 |
| Ahlenstiel, T; Ariceta, G; Bak, M; Bakkaloglu, SA; Borzych, D; Chua, A; Ha, IS; Hari, P; Klaus, G; Lipka, M; Lopez, L; Ozaltin, F; Printza, N; Rees, L; Schaefer, F; Spizzirri, AP; Valles, PG; Vogel, A; Warady, BA; Yap, HK; Zambrano, P | 1 |
| Al Saran, K; Molhem, A; Sabry, A; Yehia, A | 1 |
| Dehmel, B; Fouque, D; Jacobson, SH; Pétavy, F; Rix, M; Ryba, M; Ureña Torres, P; Zitt, E | 1 |
| Almehmi, A; Lu, J; Pregenzer, M; Quarles, LD; Shireman, TI; Wetmore, JB | 1 |
| Haller, H; Leitolf, H; Merkel, S; Schwarz, A | 1 |
| Arranz Martín, A; Azcárate Villalón, A; Carraro, R; Gómez Pan, A; Luque Ramírez, M; Marazuela Azpíroz, M; Paniagua Ruiz, A; Santana Durán, B | 1 |
| Bayés, B; Bonet, J; Casals, M; Fernández-Crespo, P; López-Ayerbe, J; Romero, R | 1 |
| Pestana Vasconcelos, M; Pinho, LR; Ribeiro Santos, MJ | 1 |
| Arkouche, W; Attaf, D; Boumendjel, N; Cardozo, C; Cardozo, J; Fouque, D; Karaaslan, H; Laville, M; Lenz, A; Mpio, I; Pastural-Thaunat, M; Silou, J | 1 |
| Akizawa, T; Fukagawa, M; Fukuhara, S; Hasegawa, T; Kido, R; Kurokawa, K; Onishi, Y; Yamaguchi, T | 1 |
| Plosker, GL | 1 |
| Arletti, S; Carboni, C; Ferrari, F; Graziani, R; Graziosi, C; Lucchi, L; Malaguti, V; Stipo, L | 1 |
| Hatamura, I; Kusano, E; Mato, M; Nakazawa, E; Ogura, M; Onishi, A; Saji, F; Shiizaki, K; Watanabe, Y | 1 |
| Martínez, AI; Milán, JA; Salgueira, M | 1 |
| Kinugasa, E; Koiwa, F; Kumata-Maeta, C; Mizobuchi, M; Ogata, H; Shishido, K; Yamamoto, M; Yoshida, N | 1 |
| Cornago, I; Gallardo, I; García-Ledesma, P; Hernando, A; Martinez, I; Montenegro, J; Muñoz, RI; Romero, MA | 1 |
| Colloton, M; Davis, J; Henley, CM; Martin, D; Miller, G; Shatzen, E | 1 |
| Alsahow, AE; Alsaran, K; Atia, M; El-Shafey, EM; Sabry, AA | 1 |
| Fukagawa, M; Kakuta, T; Koizumi, M; Komaba, H; Sawada, K; Takahashi, H; Tanaka, H | 1 |
| Allison, A; Drumheller, JC; Lockridge, R; McPhatter, L; Spiegel, DM | 1 |
| Gu, N; Jang, IJ; Kim, BH; Lee, S; Lim, KS; Shin, SG; Yu, KS | 1 |
| Imanishi, Y | 1 |
| Hashimoto, H; Hosoya, T; Ishida, M; Kimura, Y; Ohkido, I; Sekino, H; Shimada, H; Urae, J; Urashima, M; Yokoyama, K | 1 |
| Akizawa, T; Fukagawa, M; Fukuhara, S; Fukuma, S; Hasegawa, T; Kurokawa, K; Onishi, Y; Yamaguchi, T | 1 |
| Ando, T; Ito, K; Nagano, N; Yoshitaka, A | 1 |
| Barros, X; Campistol, JM; Durán, CE; Paschoalin, RP; Torregrosa, JV | 1 |
| Chen, J; Gu, Y; Hao, C; Li, H; Li, M; Ni, L; You, L; Zhang, Q | 1 |
| Barros, X; Campistol, JM; Durán, CE; Paschoalin, RP; Sánchez-Escuredo, A; Torregrosa, JV | 1 |
| Bridges, I; Christiano, C; Cooper, K; Cournoyer, SH; Covic, A; Farouk, M; Kopyt, NP; Rodriguez, M; Ureña-Torres, P; Zehnder, D | 1 |
| Abbachi, F; Abouchacra, S; Bernsen, R; Chaaban, A; Gebran, N; Haq, N; Hassan, M; Khan, I | 1 |
| Kilpatrick, RD; Liu, J; Newsome, BB; Nieman, K; Solid, CA; St Peter, WL; Zaun, D | 1 |
| Ahn, C; Chang, JH; Hwang, YH; Kim, D; Kim, H; Kim, HJ; Kim, YL; Kim, YS; Lee, J; Na, KY; Oh, KH; Shin, N; Song, YR | 1 |
| Ito, M; Koshika, M; Kudo, K; Masakane, I; Nishida, H; Nishida, W; Tanida, H; Tomita, Y | 1 |
| Albero-Molina, MD; Álvarez-Avellán, L; del Pozo-Fernández, C; López-Menchero-Martínez, R; Sánchez-Rodríguez, L | 1 |
| Adema, AY; de Borst, MH; Ter Wee, PM; Vervloet, MG | 1 |
| Carratù, AC; Colao, A; De Luca Di Roseto, C; Del Prete, M; Di Sarno, A; Di Somma, C; Esposito, R; Faggiano, A; Marciello, F; Marotta, V; Ramundo, V | 1 |
| Bravo, J; Crespo, J; Díaz, JM; García, MR; Gentil, MÁ; Gómez Alamillo, C; Gómez, G; Gutiérrez Dalmau, A; Jiménez, VL; Jimeno, L; Morales, E; Rodríguez Benot, A; Romero, R; Sáez, MJ; Torregrosa, JV | 1 |
| Biggar, P; Graf, H; Ketteler, M; Klauser-Braun, R; Kovarik, J; Müller, HW; Seidinger, S; Veres, A | 1 |
| Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Sharma, A | 1 |
| Akutsu, M; Nagata, M; Takasugi, S | 1 |
| Cooper, K; Deng, H; Evenepoel, P; Holdaas, H; Messa, P; Mourad, G; Olgaard, K; Rutkowski, B; Schaefer, H; Torregrosa, JV; Wuthrich, RP; Yue, S | 1 |
| Ballinger, AE; Craig, JC; Nistor, I; Palmer, SC; Strippoli, GF | 1 |
| Bilezikian, J; Bone, H; Gurevich, A; Khan, A; Lakatos, P; Misiorowski, W; Rozhinskaya, L; Tóth, M; Trotman, ML | 1 |
| Buerkert, J; Cooper, K; Da Roza, G; Goodman, W; Gurevich, K; Reiner, M; Sprague, SM; Wetmore, JB | 1 |
| Anker, SD; de Francisco, AL; Drüeke, TB; Floege, J; Froissart, M; Gillespie, IA; Gioni, I; Kubo, Y; Wheeler, DC | 1 |
| Lhotta, K; Mündle, M; Sprenger-Mähr, H; Zitt, E | 1 |
| Erb, H; Hemetsberger, M; Oberbauer, R; Pronai, W | 1 |
| Acosta Martínez, Y; Borrego Utiel, FJ; Bravo Soto, JA; García Álvarez, T; González Carmelo, I; López Jiménez, V; Mazuecos Blanca, MA; Merino Pérez, MJ | 1 |
| Duarte-Gallego, V; Esteve Simo, V; Fulquet Nicolas, M; Macias-Toro, J; Martínez Calvo, G; Moreno-Guzmán, F; Pou Potau, M; Ramírez-de Arellano Serna, M; Saurina Sole, A | 1 |
| Bradbury, BD; Brookhart, MA; Dluzniewski, PJ; Do, TP; Kshirsagar, AV; Reams, BD; Yue, SV | 1 |
| Chen, X; Gao, F; Hu, P; Jiang, J; Liu, H; Liu, T; Wang, H | 1 |
| Bravo, J; Castilla, YA; Esteban, MA; Esteban, RJ; Fernández-Castillo, R; García-Valverde, M; Nozal-Fernández, G; Orellana, JM | 1 |
| Akizawa, T; Fukagawa, M; Fukuhara, S; Fukuma, S; Kurita, N; Kurokawa, K; Onishi, Y; Yokoyama, K | 1 |
| Bensink, ME; Bradbury, BD; Brunelli, SM; Cooper, K; Dluzniewski, PJ; Sibbel, S | 1 |
| Alcalde-Rodrigo, M; Galicia-Basart, M; Montoro-Ronsano, JB; Pérez-Ricart, A; Segarra-Medrano, A; Suñé-Negre, JM | 1 |
| Katagiri, M; Miura, D; Nakashima, N; Ohishi, H; Shimazaki, R; Takahashi, S; Takeuchi, Y; Tominaga, Y | 1 |
| Chen, X; Liu, H; Wang, C; Yuan, F; Zhou, A | 1 |
| Cannavò, R; Cestone, G; Cirillo, L; Cutruzzulà, R; Dattolo, PC; Errichiello, C; Gallo, P; Gregori, M; Mehmetaj, A; Sorrentino, A | 1 |
| Dumrongpisutikul, N; Eiam-Ong, S; Jakchairoongruang, K; Praditpornsilpa, K; Singhan, W; Susantitaphong, P; Susomboon, T; Vadcharavivad, S | 1 |
| Barreto, FC; Bucharles, SGE; Riella, MC | 1 |
| Endo, Y; Fukagawa, M; Hamano, N; Kawata, T | 1 |
| Chon, Y; Drayer, D; Goodman, WG; Lai, J; Martin, KJ; Moore, C; Nemeth, EF; Ward, DT; Xu, J | 1 |
24 review(s) available for phosphorus and cinacalcet
| Article | Year |
|---|---|
The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials.
Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism; Naphthalenes; Phosphates; Phosphorus; Randomized Controlled Trials as Topic; Vitamin D | 2004 |
[Clinical application of calcimimetics].
Topics: Calcium; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Receptors, Calcium-Sensing | 2004 |
[Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
Topics: Animals; Calcium; Cinacalcet; Clinical Trials as Topic; Depression, Chemical; Genes, Dominant; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Mutation; Naphthalenes; Parathyroid Hormone; Phosphorus; Rats; Receptors, Calcium-Sensing | 2005 |
Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.
Topics: Calcitriol; Calcium; Cinacalcet; Humans; Hyperparathyroidism; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing | 2005 |
Secondary hyperparathyroidism: review of the disease and its treatment.
Topics: Calcium; Cinacalcet; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Renal Dialysis | 2004 |
[New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics].
Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Calcium; Cinacalcet; Diphosphonates; Drug Therapy, Combination; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Retrospective Studies; Teriparatide; Transforming Growth Factor beta; Vitamin D | 2005 |
[Management of secondary hyperparathyroidism].
Topics: Aniline Compounds; Calcinosis; Calcium; Cinacalcet; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phenethylamines; Phosphorus; Polyamines; Practice Guidelines as Topic; Propylamines; Receptors, Calcium-Sensing; Sevelamer; Vascular Diseases; Vitamin D | 2005 |
Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Topics: Animals; Area Under Curve; Calcium; Cinacalcet; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Half-Life; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Naphthalenes; Parathyroid Hormone; Parathyroid Neoplasms; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis | 2005 |
[Secondary hyperparathyroidism].
Topics: Adsorption; Blood Vessels; Calcinosis; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diagnosis, Differential; Ethanol; Humans; Hyperparathyroidism, Secondary; Injections, Intralesional; Kidney Failure, Chronic; Naphthalenes; Osteitis; Parathyroidectomy; Phosphorus; Prognosis; Renal Dialysis; Vitamin D | 2006 |
Management of chronic kidney disease mineral-bone disorder.
Topics: Bone Density Conservation Agents; Bone Diseases; Calcifediol; Chronic Disease; Cinacalcet; Diet; Humans; Hyperparathyroidism; Kidney Diseases; Kidney Failure, Chronic; Minerals; Naphthalenes; Parathyroid Hormone; Phosphates; Phosphorus; Vitamin D | 2007 |
[K-DOQI guidelines for calcium and phosphorus metabolism in chronic kidney disease: outcomes, compliance and new drugs for treatment].
Topics: Calcium; Cinacalcet; Humans; Kidney Failure, Chronic; Lanthanum; Naphthalenes; Phosphorus; Polyamines; Practice Guidelines as Topic; Sevelamer; Treatment Outcome | 2007 |
Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Topics: Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Japan; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Vitamin D | 2008 |
Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
Topics: Animals; Calcium; Cinacalcet; Drug Therapy, Combination; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing; Renal Dialysis; Risk Assessment; Treatment Outcome; Vitamin D | 2009 |
Update on the treatment of chronic kidney disease-mineral and bone disorder.
Topics: Aluminum Compounds; Calcinosis; Calcium Carbonate; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet, Protein-Restricted; Dietetics; Humans; Kidney Failure, Chronic; Lanthanum; Naphthalenes; Nephrology; Nutrition Assessment; Nutritive Value; Parathyroidectomy; Patient Care Team; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Sevelamer; Vitamin D | 2009 |
Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U".
Topics: Calcium; Cinacalcet; Clinical Trials as Topic; Comorbidity; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcitriol; Treatment Outcome; Vitamins | 2009 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality].
Topics: Bone Diseases, Metabolic; Calcinosis; Calcium; Chronic Disease; Cinacalcet; Humans; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Polyamines; Prognosis; Risk; Sevelamer; Survival Rate; Vascular Diseases; Vitamin D | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
Topics: Bone Diseases, Metabolic; Calcinosis; Calcium; Chronic Disease; Cinacalcet; Clinical Trials as Topic; Drug Therapy, Combination; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Vascular Diseases; Vitamin D | 2010 |
Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.
Topics: Calcium; Cinacalcet; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2011 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Bone fragility in the aged hemodialysis patients].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diphosphonates; Fractures, Spontaneous; Homeostasis; Humans; Kidney Diseases; Minerals; Naphthalenes; Osteoporosis; Phosphorus; Renal Dialysis; Risk | 2012 |
[Cinacalcet hydrochloride and phosphate metabolism].
Topics: Animals; Calcium; Cinacalcet; Humans; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic | 2012 |
Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis.
Topics: Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Odds Ratio; Patient Safety; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis; Treatment Outcome | 2012 |
Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
Topics: Calcium; Calcium, Dietary; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Diet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Naphthalenes; Phosphorus; Phosphorus, Dietary; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2014 |
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Topics: Calcimimetic Agents; Calcium; Cardiovascular Diseases; Cause of Death; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis | 2014 |
Development of evocalcet for unmet needs among calcimimetic agents.
Topics: Calcimimetic Agents; Calcium; Cinacalcet; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Japan; Naphthalenes; Phosphorus; Pyrrolidines; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic | 2020 |
38 trial(s) available for phosphorus and cinacalcet
| Article | Year |
|---|---|
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Topics: Adult; Aged; Calcitriol; Calcium; Calcium Channel Agonists; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Titrimetry | 2003 |
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
Topics: Adult; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing; Receptors, Cell Surface; Renal Dialysis; Vitamin D | 2003 |
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Topics: Calcium; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2004 |
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
Topics: Adult; Aged; Bone and Bones; Calcium; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus | 2005 |
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Topics: Administration, Oral; Adult; Calcium; Cinacalcet; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peritoneal Dialysis; Phosphorus; Renal Dialysis; Vitamin D | 2005 |
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
Topics: Calcium; Chronic Disease; Cinacalcet; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Treatment Outcome; Vitamin D | 2005 |
Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing; Time Factors | 2005 |
First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.
Topics: Adult; Aged; Calcium; Cinacalcet; Drug Monitoring; Female; Humans; Hyperparathyroidism; Immunoassay; Linear Models; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Treatment Outcome; Vitamin D | 2005 |
Cinacalcet in the management of tumor-induced osteomalacia.
Topics: Bone and Bones; Calcitriol; Calcium; Cinacalcet; Drug Therapy, Combination; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hydrochlorothiazide; Hypoparathyroidism; Hypophosphatemia; Kidney; Male; Middle Aged; Naphthalenes; Neoplasms; Osteomalacia; Parathyroid Hormone; Phosphates; Phosphorus; Treatment Outcome; Vitamin D | 2007 |
Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients.
Topics: Calcium; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism; Japan; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2008 |
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Calcium; Chelating Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Treatment Outcome; Vitamin D | 2008 |
Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Topics: Adult; Aged; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Severity of Illness Index; Sterols; Treatment Outcome; Vitamin D | 2008 |
Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.
Topics: Acid Phosphatase; Aged; Asian People; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Isoenzymes; Japan; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Osteocalcin; Parathyroid Hormone; Phosphorus; Renal Dialysis; Tartrate-Resistant Acid Phosphatase | 2008 |
Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants.
Topics: Analysis of Variance; Calcium; Cinacalcet; Creatinine; Female; Gastric Acid; Gastric Juice; Gastric Mucosa; Gastrins; Humans; Magnesium; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing; Stimulation, Chemical | 2009 |
Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Topics: Adult; Aged; Calcium; Chronic Disease; Cinacalcet; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Prospective Studies; Renal Dialysis; Time Factors; Treatment Outcome; Vitamin D; Vitamins | 2008 |
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Topics: Aged; Calcium; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2009 |
Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Topics: Adult; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Male; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Vitamin D | 2009 |
Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.
Topics: Adult; Aged; Biomarkers; Calcium; Canada; Chelating Agents; Chronic Disease; Cinacalcet; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peritoneal Dialysis; Phosphates; Phosphorus; Renal Dialysis; Time Factors; Treatment Outcome; United States; Vitamin D | 2009 |
Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?
Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Renal Dialysis; Severity of Illness Index; Treatment Outcome | 2009 |
Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Topics: Adult; Aged; Calcium; Cinacalcet; Cost-Benefit Analysis; Decision Support Techniques; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Quality-Adjusted Life Years; Renal Dialysis; Treatment Outcome; United States; Vitamin D | 2010 |
The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism.
Topics: Aged; Biopsy; Bone and Bones; Calcium; Cinacalcet; Creatinine; Female; Glomerular Filtration Rate; Homeostasis; Humans; Hyperparathyroidism; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Nephrocalcinosis; Parathyroid Hormone; Phosphorus; Prospective Studies | 2011 |
[Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Asthenia; Calcium; Cinacalcet; Contraindications; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Male; Middle Aged; Naphthalenes; Nausea; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Prospective Studies; Vitamin D | 2011 |
Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.
Topics: Aged; Calcium; Cinacalcet; Cohort Studies; Female; Humans; Hyperparathyroidism, Secondary; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Patterns, Physicians'; Renal Dialysis | 2011 |
Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
Topics: Adult; Aged; Calcimimetic Agents; Calcium; Chronic Disease; Cinacalcet; Compassionate Use Trials; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Severity of Illness Index; Treatment Outcome; Vitamin D | 2012 |
Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Bone Density Conservation Agents; Chelating Agents; Cinacalcet; Female; Femur; Humans; Hyperparathyroidism, Secondary; Lumbar Vertebrae; Male; Middle Aged; Naphthalenes; Phosphorus; Prospective Studies; Pruritus; Renal Dialysis; Treatment Outcome; Vitamin D | 2011 |
Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism.
Topics: Aged; Calcimimetic Agents; Calcium; Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Phosphorus; Renal Dialysis; Treatment Outcome | 2012 |
A computerized treatment algorithm trial to optimize mineral metabolism in ESRD.
Topics: Aged; Algorithms; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Drug Substitution; Drug Therapy, Computer-Assisted; Female; Humans; Kidney Failure, Chronic; Longitudinal Studies; Male; Metabolic Diseases; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Time Factors; Treatment Outcome; Vitamin D; Vitamins | 2012 |
Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study.
Topics: Administration, Oral; Adult; Area Under Curve; Calcium; Chromatography, High Pressure Liquid; Cinacalcet; Dose-Response Relationship, Drug; Humans; Male; Naphthalenes; Parathyroid Hormone; Phosphorus; Republic of Korea; Serum Albumin; Tandem Mass Spectrometry; Young Adult | 2012 |
Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
Topics: Adult; Aged; Calcium; Case-Control Studies; Cinacalcet; Cohort Studies; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; International Agencies; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prognosis; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D; Vitamins | 2013 |
A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.
Topics: Adult; Aged; Alkaline Phosphatase; Calcimimetic Agents; Calcium; Cinacalcet; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Medication Adherence; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Pilot Projects; Prospective Studies; Renal Dialysis; Severity of Illness Index | 2014 |
Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study.
Topics: Adult; Aged; Biomarkers; Calcium; Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peritoneal Dialysis; Phosphorus; Vitamin D | 2013 |
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Ergocalciferols; Female; Fibroblast Growth Factor-23; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Injections, Intravenous; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism.
Topics: Adult; Bone Density; Bone Remodeling; Calcium; Cinacalcet; Double-Blind Method; Female; Humans; Hypercalcemia; Hyperparathyroidism; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Phosphorus; Placebos | 2014 |
Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
Topics: Adult; Aged; Aged, 80 and over; Cinacalcet; Contraindications; Double-Blind Method; Endpoint Determination; Female; Humans; Hypercalcemia; Hyperparathyroidism; Male; Middle Aged; Naphthalenes; Parathyroidectomy; Phosphorus | 2015 |
Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Topics: Aged; Australia; Biomarkers; Calcimimetic Agents; Calcium; Canada; Chi-Square Distribution; Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Risk Factors; Russia; Time Factors; Treatment Outcome; United States; Vitamin D | 2015 |
Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study.
Topics: Adult; Area Under Curve; Asian People; Calcium; Chromatography, High Pressure Liquid; Cinacalcet; Dose-Response Relationship, Drug; Female; Humans; Longitudinal Studies; Male; Parathyroid Hormone; Phosphorus; Tandem Mass Spectrometry; United States; Young Adult | 2016 |
Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
Topics: Adult; Aged; Asian People; Calcium; Calcium, Dietary; Cinacalcet; Creatinine; Demography; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Male; Middle Aged; Parathyroid Hormone; Parathyroid Neoplasms; Phosphorus; Vital Signs | 2017 |
The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
Topics: Adult; Calcimimetic Agents; Calcium; Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Severity of Illness Index; Treatment Outcome; Young Adult | 2019 |
67 other study(ies) available for phosphorus and cinacalcet
| Article | Year |
|---|---|
Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.
Topics: Animals; Calcitonin; Calcium; Calcium-Binding Proteins; Cells, Cultured; Cinacalcet; Humans; Male; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley | 2004 |
Fooling the parathyroid gland--will there be health benefits?
Topics: Calcium; Cinacalcet; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Vitamin D | 2004 |
Clinical experience with cinacalcet HCl.
Topics: Alkaline Phosphatase; Cinacalcet; Clinical Trials, Phase III as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Glands; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis | 2004 |
1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
Topics: Animals; Aortic Diseases; Calcinosis; Calcitriol; Calcium; Calcium Channel Agonists; Chronic Disease; Cinacalcet; Disease Models, Animal; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Naphthalenes; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley | 2005 |
Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats.
Topics: Animals; Calcium; Calcium Oxalate; Calcium Phosphates; Calcium, Dietary; Cinacalcet; Female; Kidney Calculi; Naphthalenes; Parathyroid Hormone; Phosphorus; Rats; Rats, Mutant Strains; Receptors, Calcium-Sensing; Urinary Calculi | 2006 |
Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients.
Topics: Acetates; Calcitriol; Calcium; Calcium Compounds; Chronic Disease; Cinacalcet; Clinical Trials, Phase III as Topic; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic | 2006 |
Does cinacalcet safely and effectively maintain long-term PTH control in secondary hyperparathyroidism?
Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing; Time Factors; Vitamin D | 2006 |
Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease.
Topics: Adult; Cinacalcet; Humans; Kidney Failure, Chronic; Naphthalenes; Phosphate-Binding Proteins; Phosphorus; Polyamines; Renal Dialysis; Sevelamer | 2006 |
Achieving targets for bone and mineral metabolism: the impact of cinacalcet HCl in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Retrospective Studies; Treatment Outcome | 2006 |
Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.
Topics: Adolescent; Calcium; Cinacalcet; Diagnosis, Differential; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Male; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Phosphorus | 2006 |
Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation.
Topics: Adult; Aged; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Phosphorus; Retrospective Studies | 2007 |
Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
Topics: Adult; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Prospective Studies; Recurrence; Retreatment; Treatment Outcome | 2007 |
Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis.
Topics: Calcium; Cinacalcet; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gastrointestinal Hormones; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Radioimmunoassay; Renal Dialysis; Severity of Illness Index; Substance P; Treatment Outcome; Vasoactive Intestinal Peptide | 2008 |
[Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].
Topics: Aged; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing; Renal Dialysis | 2008 |
Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Primary; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Treatment Outcome | 2008 |
Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease.
Topics: Adolescent; Adult; Calcium; Child; Child, Preschool; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Infant; Kidney Failure, Chronic; Male; Naphthalenes; Parathyroid Hormone; Phosphorus | 2008 |
Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose.
Topics: Adult; Aged; Calcium; Cinacalcet; Cyclosporine; Dose-Response Relationship, Drug; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Tacrolimus | 2008 |
Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.
Topics: Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies | 2008 |
Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
Topics: Animals; Biomarkers; Calcium; Cinacalcet; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Treatment Outcome | 2008 |
Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.
Topics: Calcium; Cinacalcet; Cost-Benefit Analysis; Ethanol; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Glands; Parathyroidectomy; Phosphorus; Quality of Life; Survival Rate | 2008 |
Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Topics: Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Renal Dialysis; Treatment Outcome; Vitamin D | 2008 |
Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
Topics: Calcium; Cinacalcet; Guidelines as Topic; Humans; Hyperparathyroidism, Secondary; Japan; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis; Societies, Medical | 2008 |
Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.
Topics: Adolescent; Adult; Biomarkers; Calcium; Centers for Medicare and Medicaid Services, U.S.; Cinacalcet; Databases as Topic; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Drug Utilization Review; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Outcome and Process Assessment, Health Care; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Practice Patterns, Physicians'; Renal Dialysis; Time Factors; Treatment Outcome; United States; Vitamin D; Young Adult | 2009 |
Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story.
Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Hypocalcemia; Kidney Failure, Chronic; Naphthalenes; Phosphorus | 2009 |
Caring for chronic kidney disease patients: focus on mineral and bone disorders.
Topics: Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet Therapy; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Metabolic Diseases; Middle Aged; Naphthalenes; Parathyroid Hormone; Pharmaceutical Services; Phosphorus; Receptors, Calcium-Sensing; Renal Dialysis; Vitamin D | 2009 |
Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
Topics: Adult; Aged; Bone and Bones; Calcium; Cinacalcet; Europe; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Minerals; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Vitamin D | 2009 |
Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism.
Topics: Acid Phosphatase; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Regeneration; Bone Remodeling; Bone Resorption; Calcium; Cinacalcet; Drug Administration Schedule; Female; Hormone Antagonists; Humans; Hyperparathyroidism, Secondary; Isoenzymes; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Tartrate-Resistant Acid Phosphatase; Time Factors | 2010 |
Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.
Topics: Biomarkers; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Time Factors; Treatment Outcome; Vitamin D | 2009 |
Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Topics: Attitude of Health Personnel; Biomarkers; Bone Diseases, Metabolic; Calcium; Chelating Agents; Chronic Disease; Cinacalcet; Evidence-Based Medicine; Glomerular Filtration Rate; Guideline Adherence; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Practice Patterns, Physicians'; Renal Dialysis; Saudi Arabia; Surveys and Questionnaires; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2010 |
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
Topics: Animals; Biomarkers; Bone Resorption; Calcitriol; Calcium; Cinacalcet; Creatinine; Disease Models, Animal; Ergocalciferols; Female; Fibroblast Growth Factors; Hyperparathyroidism; Hyperphosphatemia; Hypocalcemia; Naphthalenes; Nephrectomy; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Severity of Illness Index; Tibia; Uremia | 2010 |
Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism.
Topics: Acid Phosphatase; Adult; Aged; Bone Remodeling; Calcium; Cinacalcet; Collagen Type I; Female; Humans; Hyperparathyroidism, Secondary; Isoenzymes; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peptides; Phosphorus; Renal Dialysis; Tartrate-Resistant Acid Phosphatase; Uremia | 2011 |
The bone and mineral disorder of children undergoing chronic peritoneal dialysis.
Topics: Adolescent; Calcium; Child; Child, Preschool; Cinacalcet; Europe; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Hypocalcemia; Infant; Kidney Failure, Chronic; Latin America; Male; Naphthalenes; North America; Parathyroid Hormone; Peritoneal Dialysis; Phosphate-Binding Proteins; Phosphorus; Prospective Studies; Registries; Vitamin D; Young Adult | 2010 |
Cinacalcet effect on severe hyperparathyroidism.
Topics: Administration, Oral; Adult; Biomarkers; Calcium; Cinacalcet; Dietary Supplements; Egypt; Female; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Severity of Illness Index; Time Factors; Treatment Outcome; Vitamin D | 2010 |
Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.
Topics: Aged; Calcium; Cinacalcet; Cohort Studies; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Recurrence; Renal Dialysis; Survival Rate; Treatment Outcome; Vitamin D | 2011 |
Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study.
Topics: Adult; Aged; Alkaline Phosphatase; Aorta; Aortic Diseases; Biomarkers; Blood Pressure; Calcimimetic Agents; Calcium; Cinacalcet; Elasticity; Female; Humans; Hyperparathyroidism, Secondary; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Pulsatile Flow; Renal Dialysis; Spain; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2011 |
Cinacalcet in the treatment of persistent hyperparathyroidism after kidney transplantation.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Retrospective Studies; Time Factors; Treatment Outcome | 2011 |
[Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Anemia, Iron-Deficiency; Biomarkers; Calcium; Calcium Phosphates; Cinacalcet; Drug Resistance; Drug Therapy, Combination; Female; Hematinics; Hemoglobins; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Phosphorus; Pilot Projects; Prospective Studies; Renal Dialysis; Treatment Outcome | 2011 |
Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Cinacalcet; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2011 |
Development and prevention of morphologic and ultrastructural changes in uremia-induced hyperplastic parathyroid gland.
Topics: Animals; Calcitriol; Capillaries; Cinacalcet; Disease Models, Animal; Hyperparathyroidism, Secondary; Hyperplasia; Male; Naphthalenes; Nephrectomy; Organelles; Parathyroid Glands; Phosphorus; Phosphorus, Dietary; Rats; Rats, Sprague-Dawley; Uremia | 2011 |
Regression of vascular calcification in a patient treated with cinacalcet: a case report.
Topics: Breast; Calcimimetic Agents; Calcitriol; Calcium Carbonate; Chelating Agents; Cinacalcet; Drug Therapy, Combination; Female; Graft Rejection; Hand; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Mammography; Middle Aged; Naphthalenes; Nephritis, Interstitial; Phosphorus; Polyamines; Renal Dialysis; Reoperation; Sevelamer; Vascular Calcification | 2011 |
Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism.
Topics: Adolescent; Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Diseases; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Prospective Studies; Treatment Outcome; Ultrasonography; Young Adult | 2012 |
Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.
Topics: Animals; Calcium; Cell Proliferation; Cinacalcet; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Failure, Chronic; Male; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Uremia | 2012 |
Cinacalcet for hemodialyzed patients with or without a high PTH level to control serum calcium and phosphorus: ECO (evaluation of cinacalcet HCl outcome) study.
Topics: Calcium; Cinacalcet; Cohort Studies; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis | 2012 |
Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.
Topics: Aged; Biomarkers; Bone Diseases, Metabolic; Calcimimetic Agents; Calcium; Cinacalcet; Drug Prescriptions; Drug Utilization; Drug Utilization Review; Female; Humans; Hyperparathyroidism, Secondary; Japan; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Patterns, Physicians'; Prevalence; Prospective Studies; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Vitamin D | 2012 |
Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
Topics: Adult; Aged; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Creatinine; Drug Administration Schedule; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Time Factors; Treatment Outcome | 2012 |
Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.
Topics: Alkaline Phosphatase; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Creatinine; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Immunosuppressive Agents; Kidney Transplantation; Male; Naphthalenes; Parathyroid Hormone; Phosphorus; Radioimmunoassay; Retrospective Studies; Time Factors; Treatment Outcome | 2012 |
Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients.
Topics: Adolescent; Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Injections, Intravenous; Male; Middle Aged; Naphthalenes; Parathyroid Neoplasms; Phosphorus; Renal Dialysis; United States; Vitamin D; Young Adult | 2013 |
Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
Topics: Adult; Aged; Algorithms; Bone Diseases, Metabolic; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Sterols; Time Factors; Vitamin D | 2013 |
Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term.
Topics: Aged; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Ergocalciferols; Female; Follow-Up Studies; Goals; Guideline Adherence; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Peritoneal Dialysis; Phosphorus; Postoperative Complications; Practice Guidelines as Topic; Renal Dialysis; Retrospective Studies | 2013 |
Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Topics: Adult; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Primary; Middle Aged; Mothers; Multiple Endocrine Neoplasia Type 1; Naphthalenes; Nuclear Family; Parathyroid Hormone; Pedigree; Phosphorus; Treatment Outcome | 2013 |
Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study.
Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Retrospective Studies | 2014 |
Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
Topics: Aged; Alkaline Phosphatase; Austria; Bone Density Conservation Agents; Calcimimetic Agents; Calcium; Cinacalcet; Ergocalciferols; Female; Germany; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
Oral phosphorus supplementation secondarily increases circulating fibroblast growth factor 23 levels at least partially via stimulation of parathyroid hormone secretion.
Topics: Animals; Cinacalcet; Dietary Supplements; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Naphthalenes; Parathyroid Hormone; Phosphates; Phosphorus; Phosphorus, Dietary; Rats, Wistar; Receptors, Calcium-Sensing | 2014 |
Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.
Topics: Adult; Aged; Bias; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Mortality; Observational Studies as Topic; Phosphorus; Propensity Score; Renal Dialysis | 2015 |
Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency.
Topics: Administration, Oral; Aged; Aged, 80 and over; Body Weight; Calcifediol; Calcimimetic Agents; Calcitriol; Calcium; Cholecalciferol; Cinacalcet; Drug Dosage Calculations; Drug Substitution; Female; Humans; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D Deficiency; Vitamins | 2015 |
EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice.
Topics: Adult; Aged; Austria; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Product Surveillance, Postmarketing; Renal Dialysis | 2015 |
Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Cinacalcet; Drug Substitution; Drug Therapy, Combination; Ergocalciferols; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Postoperative Complications; Retrospective Studies | 2015 |
Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
Topics: Aged; Ambulatory Care; Calcimimetic Agents; Calcium; Cinacalcet; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Patient Satisfaction; Phosphorus; Prospective Studies; Renal Dialysis; Therapeutic Equivalency; Visual Analog Scale | 2015 |
Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.
Topics: Adult; Aged; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Income; Insurance Coverage; Kidney Failure, Chronic; Male; Medicare Part D; Middle Aged; Parathyroid Hormone; Phosphorus; Public Assistance; Renal Dialysis; Retreatment; Retrospective Studies; Serum Albumin; United States; Withholding Treatment | 2015 |
Use of cinacalcet for the management of hyperparathyroidism in patients with different degrees of renal failure.
Topics: Adult; Aged; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2016 |
Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.
Topics: Aged; Biomarkers; Calcimimetic Agents; Calcitriol; Calcium; Cinacalcet; Cohort Studies; Female; Humans; Hyperparathyroidism, Secondary; Japan; Kidney Failure, Chronic; Male; Middle Aged; Minerals; Parathyroid Hormone; Patient Care Planning; Phosphorus; Renal Dialysis; Vitamins | 2017 |
The association between cinacalcet use and missed in-center hemodialysis treatment rate.
Topics: Adult; Aged; Calcimimetic Agents; Calcium; Cinacalcet; Health Status; Humans; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Retrospective Studies; Vitamin D | 2016 |
Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.
Topics: Aged; Aged, 80 and over; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Off-Label Use; Parathyroid Hormone; Phosphorus; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2016 |
[Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
Topics: Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcimimetic Agents; Calcitriol; Calcium; Cinacalcet; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Osteocalcin; Parathyroid Hormone; Phosphorus; Renal Dialysis; Treatment Outcome | 2017 |
[Dystrophic Calcinosis Cutis: a rare fearsome issue of Chronic Kidney Disease].
Topics: Calcinosis; Chelation Therapy; Cinacalcet; Female; Glomerulonephritis, Membranous; Hand Deformities, Acquired; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Middle Aged; Peritoneal Dialysis; Phosphorus; Skin Diseases; Vitamin D | 2018 |
The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Topics: Adult; Aged; Alkaline Phosphatase; Calcimimetic Agents; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Hypocalcemia; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Retrospective Studies; Treatment Outcome; Vitamin D | 2019 |
Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
Topics: Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Middle Aged; Parathyroid Hormone; Peptides; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies | 2022 |